Journal article
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421
Abstract
BACKGROUND: Phase 2 trials evaluating new agents for metastatic castration-resistant prostate cancer (mCRPC) have relied on bone scan and prostate-specific antigen changes to assess activity. Given the increasing detection of measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST) changes warrant consideration to evaluate activity. We validated the association of RECIST 1.0 changes with survival in men with mCRPC receiving …
Authors
Sonpavde G; Pond GR; Plets M; Tangen CM; Hussain MHA; Lara PN; Goldkorn A; Garzotto MG; Mack PC; Higano CS
Journal
Clinical Genitourinary Cancer, Vol. 15, No. 6, pp. 635–641
Publisher
Elsevier
Publication Date
December 2017
DOI
10.1016/j.clgc.2017.05.014
ISSN
1558-7673